- Home
- RRC vs CORT Comparison
RRC vs CORT Comparison
Compare RRC & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRC
- CORT
- Stock Information
- Founded
- RRC 1976
- CORT 1998
- Country
- RRC United States
- CORT United States
- Employees
- RRC N/A
- CORT N/A
- Industry
- RRC Oil & Gas Production
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- RRC Energy
- CORT Health Care
- Exchange
- RRC Nasdaq
- CORT Nasdaq
- Market Cap
- RRC 8.0B
- CORT 7.5B
- IPO Year
- RRC N/A
- CORT N/A
- Fundamental
- Price
- RRC $38.27
- CORT $71.72
- Analyst Decision
- RRC Hold
- CORT Strong Buy
- Analyst Count
- RRC 18
- CORT 4
- Target Price
- RRC $42.82
- CORT $142.00
- AVG Volume (30 Days)
- RRC 2.7M
- CORT 1.6M
- Earning Date
- RRC 07-22-2025
- CORT 07-28-2025
- Dividend Yield
- RRC 0.94%
- CORT N/A
- EPS Growth
- RRC N/A
- CORT 8.36
- EPS
- RRC 1.11
- CORT 1.14
- Revenue
- RRC $2,610,836,000.00
- CORT $685,446,000.00
- Revenue This Year
- RRC $30.28
- CORT $35.83
- Revenue Next Year
- RRC $12.68
- CORT $35.24
- P/E Ratio
- RRC $34.34
- CORT $62.92
- Revenue Growth
- RRC 12.00
- CORT 30.93
- 52 Week Low
- RRC $27.29
- CORT $30.77
- 52 Week High
- RRC $43.50
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- RRC 42.80
- CORT 50.50
- Support Level
- RRC $36.85
- CORT $66.49
- Resistance Level
- RRC $39.15
- CORT $72.49
- Average True Range (ATR)
- RRC 1.07
- CORT 2.85
- MACD
- RRC -0.44
- CORT -0.09
- Stochastic Oscillator
- RRC 21.35
- CORT 49.95
About RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.